The large randomized, controlled trials of therapeutic hypothermia for hypoxic-ischemic encephalopathy excluded neonates with congenital disorders. The objective of this study was to report our experience using hypothermia in neonates with signs of hypoxic-ischemic encephalopathy and a syndromic disorder or brain anomaly. Subjects were identified from a database of neonates admitted to the Neuro-Intensive Care Nursery at University of California, San Francisco. Of 169 patients fulfilling criteria for hypothermia, 8 (5%) had a syndromic disorder and were cooled per guidelines for nonsyndromic neonates. Perinatal characteristics of infants with and without syndromic disorder were not significantly different. Overall outcome was poor: 38% had evidence of acute hypoxic-ischemic injury, 3 subjects died, and 2 survivors had low developmental quotient (ie, 25). The risk versus benefit of therapeutic hypothermia for hypoxic-ischemic encephalopathy among neonates with congenital brain malformations or syndromic diagnoses is uncertain.
Hypoxic-ischemic encephalopathy occurs in 1 to 2 per 1000 live births, and is one of the primary causes of long-term neurologic disabilities in children. 1 Therapeutic hypothermia is the only known effective neuroprotective therapy and is standard of care for term neonates with hypoxic-ischemic encephalopathy to reduce death or disability at 18 to 24 months of age. [2] [3] [4] The large randomized, controlled trials of hypothermia shared well-defined eligibility criteria, and neonates at risk for adverse outcome independent hypoxicischemic encephalopathy (ie, with recognizable congenital anomalies) were excluded. As such, little is known about the outcome of therapeutic hypothermia in term infants with congenital brain anomalies or syndromic disorders and hypoxic-ischemic encephalopathy.
In 2007, our center initiated a therapeutic hypothermia program that did not automatically exclude neonates with congenital brain anomalies or syndromic disorders, as long as they met all other local institutional guidelines for therapeutic hypothermia. The objective of this study was to report our center's experience with these patients who would not have qualified for the randomized trials. score <5, or prolonged resuscitation. Encephalopathy was defined by altered mental status, abnormal tone or reflexes, absent or weak suck, and/or seizures. Children born at outside institutions were passively cooled during transport. Active whole-body cooling was accomplished via a blanket cooling device (Cincinnati Subzero Blanketrol III, Cincinnati, OH). Core temperatures as measured by a rectal probe were maintained at 33.5 C for 72 hours. Both video electroencephalography (EEG) and amplitude-integrated EEG monitoring were used throughout the duration of cooling and the 24-hour period after rewarming.
Patients with congenital brain anomalies or syndromic disorders were identified on the basis of any one of the following: (1) physical examination findings, (2) genetic, or (3) imaging studies. Medical records were reviewed, including reports from the Intensive Care Nursery Follow Up Program, as well as the Neonatal Neurology Clinic.
Subjects were studied with magnetic resonance imaging (MRI) of the brain at a median of 4 days of life (interquartile range, 4-5) using conventional and diffusion-weighted imaging, as well as magnetic resonance spectroscopy. A pediatric neuroradiologist interpreted all MRI studies.
Outcome was reported using neuropsychological assessment or developmental quotient. For subjects who were able to complete formal neuropsychological testing, the Bayley Scales of Infant Development, 3rd edition, were administered to subjects 36 months of age, and the Wechsler Preschool and Primary Scales of Intelligence III were administered to subjects >36 months old. For subjects who could not complete formal testing, a developmental quotient was calculated as the estimated developmental age divided by the chronological age. Outcome was reported as (1) 
Results
Of 169 eligible participants who met the perinatal criteria for therapeutic hypothermia, 8 (5%) neonates had a congenital brain anomaly or syndromic disorder. The subjects with and without anomalies did not differ with regard to gender, gestational age, birth weight, or other perinatal characteristics at the time of presentation as listed in Table 1 .
Subjects with congenital anomalies or syndromic disorders fell into 3 groups: the first group, nonspecific syndromes, contained 2 subjects who had dysmorphic craniofacial features without identified etiology, the second group of isolated brain malformations had 1 subject, and the third group, named syndromes, had 5 subjects.
Overall outcome was poor ( Table 2 ). Six of the 8 subjects had abnormal MRI findings (75%). Four (50%) had brain malformations, whereas the remainder had structurally normal brains. Three subjects (38%) had imaging evidence of acute hypoxic-ischemic injury. The mortality rate was high: 3 subjects (38%) died in the neonatal period. Of the survivors, 4 were seen at a median age of 26 months (interquartile range ¼ 24-40), 3 with unfavorable outcome as detailed below.
Nonspecific Syndrome
Two of the neonates had a nonspecific syndromic disorder identified at the time of birth based on dysmorphic features. In both subjects, no underlying etiology was found.
For the first patient, dysmorphic features (low anterior hair line, bitemporal narrowing, posteriorly rotated ears, midfacial hypoplasia, upturned nose with a depressed nasal bridge, broad-spaced nipples, and hypoplastic nails with fifth toe clinodactyly) were noted at birth, and he was seen in consultation by the genetics service on the day of birth. EEG, MRI, and high-resolution chromosomes were normal. At 28 months of age, Bayley Scales of Infant Development, 3rd edition, composite cognitive score was in the very superior range (140), and language and motor function were average (97 and 103).
In the second patient, dysmorphic features (midface hypoplasia and bulbous nose) were noted on admission, and she was seen in consultation by the genetics service on the third day of life. EEG was abnormal because of mild diffuse voltage attenuation. MRI and high-resolution chromosomes were normal. Her last evaluation was in the intensive care nursery at 11 days of life, with neurologic examination notable for mild axial hypotonia and monophasic moro reflex.
Isolated Brain Malformation
One subject was diagnosed with a brain malformation. Neurosonogram on the second day of life showed a small cerebellum; pontocerebellar hypoplasia was confirmed by MRI. The EEG was abnormal because of excess discontinuity. On the fourth day of life, the parents opted to transition care to palliative measures, and the patient died shortly thereafter.
Named Disorder
In 5 subjects, a named disorder was identified: Treacher Collins, Emanuel, Joubert Plus, and Wiedemann-Steiner syndromes, and presumed congenital myotonic dystrophy.
Craniofacial features consistent with Treacher Collins syndrome were noted in this patient at birth. MRI showed There were no differences between subjects with and without a congenital brain anomaly or syndromic disorder. Data are presented as n (%), median (interquartile range), or mean (+ standard deviation). abnormal areas of T1 shortening and reduced diffusion in the depths of the central sulci, posterior insula, and deep gray nuclei bilaterally in keeping with acute hypoxic-ischemic injury. Because of brain injury and medical need for tracheostomy, the parents opted to transition care to palliative measures and the patient died shortly thereafter. For the patient with Emanuel syndrome, dysmorphic craniofacial features were noted at birth (bilateral absence of the ears, retrognathia, mandibular hypoplasia, multiple auricular pits, cleft chin, and right facial paresis) and he was evaluated by the genetics service on the second day of life. MRI showed diffuse hyperintensity of the white matter and low metabolite peaks, and 2 areas of focal, noncystic white matter injury. Comparative genomic hybridization array in the neonatal period showed findings that were in keeping with Emanuel syndrome. At 24 months of age, the patient had minimal to no expressive language and inability to maintain sitting position for prolonged times (developmental quotient *25).
For the patient with Joubert Plus syndrome, congenital brain malformation was suspected on fetal ultrasound and confirmed by fetal MRI, which demonstrated cerebellar vermian hypoplasia with thickened cerebellar peduncles (''molar tooth'' sign), and polymicrogyria. Dysmorphic craniofacial features (hypertelorism, broad nasal bridge, and unilateral coloboma) and preaxial polydactyly were noted at birth. Postnatal MRI confirmed the malformations that were noted on the fetal study, and also showed a focal area of reduced diffusion within the right occipital lobe. At 24 months of age, the patient had minimal expressive language and sits with assistance (developmental quotient *25).
The patient with Wiedemann-Steiner syndrome was not evaluated by the genetics service until 1 month, when the primary team felt that poor feeding that was out of keeping for the degree of hypoxia-ischemia, and also noted dysmorphic craniofacial features. She was initially thought to have Cornelia de Lange syndrome based on her craniofacial features; however, genetic testing at age 6 confirmed Wiedemann-Steiner syndrome. The MRI showed global volume loss with marked symmetric white matter loss and a focal area of T1 shortening within the right posterior putamen, consistent with chronic changes. The patient had a formal developmental assessment using Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 51 months of age and scored borderline in verbal (77) and extremely low in performance skills (49).
The patient with presumed congenital myotonic dystrophy was noted to have subtle dysmorphic craniofacial features (hypertelorism, cloudy corneas, and low-set ears) at the time of admission. MRI showed simplified sulcation and cerebellar hypoplasia, as well as reduced diffusion in the periventricular white matter, consistent with both congenital malformation and acute/subacute hypoxic-ischemic injury. Comparative genomic hybridization array and testing for inborn errors of metabolism were normal. On the fourth day of life, the parents opted to transition care to palliative measures, and the patient died shortly thereafter. The mother subsequently had a second child with similar presentation who was diagnosed with congenital myotonic dystrophy.
Discussion
Among 169 infants treated with therapeutic hypothermia, we identified 5% who would have been excluded from the randomized, controlled trials because of dysmorphic craniofacial features, a syndromic diagnosis, and/or congenital brain anomaly. Six of the 8 subjects (75%) had a suspected underlying diagnosis at the time of the decision to proceed with therapeutic hypothermia. All subjects qualified for therapeutic hypothermia based on Apgar scores, pH or base excess, or need for prolonged resuscitation, as well as neurologic examination indicating encephalopathy. It is not known whether resuscitation or examination features were affected by underlying diagnosis such that the patient appeared to qualify for hypothermia but was presenting signs or symptoms of the syndrome rather than hypoxic-ischemic injury. Three subjects (38%) were deceased in the neonatal period, and 3 of 5 survivors had an unfavorable developmental outcome.
The large randomized, controlled trials of therapeutic hypothermia for perinatal hypoxic-ischemic encephalopathy excluded subjects with recognizable congenital anomalies. 2 The reason for excluding these subjects from the trials is 2-fold. First, syndromic diagnoses and congenital anomalies often confer a risk for adverse developmental outcome that is independent of hypoxic-ischemic injury. Several large studies indicated that restricted growth and/or congenital anomalies are important risk factors for death and cerebral palsy. [5] [6] [7] [8] Second, it may be impossible to distinguish neonates with encephalopathy due to hypoxic-ischemic brain injury, from those with abnormal neurologic examination due to underlying congenital anomalies. Badawi et al examined a large cohort of term infants with moderate or severe encephalopathy in Western Australia, and found birth defects among 23.2% of affected infants. 5 In a separate study, the same group and found a strong association between birth defects and encephalopathy: birth defects were found in 27.5% of neonates with encephalopathy, as compared with only 4.3% of those without. 9 The birth defect was considered the probable cause of the encephalopathy in only 36%, suggesting that other causes of encephalopathy, such as hypoxia-ischemia, may be more common in the setting of birth defects. As such, it is impossible to know whether the abnormal neurologic findings among the subjects presented here was due to the underlying anomaly or due to acute brain injury. In all cases, the attending neonatologist and/or neurologist decided that the potential benefit of therapeutic hypothermia outweighed the risks.
Our study is limited by a relatively small sample size and retrospective design. Furthermore, follow up was variable among subjects. Finally, we were not able to capture subjects that were not cooled, either by our center or outside referral centers, so we cannot determine the true proportion of neonates that may present with both signs of hypoxic-ischemic encephalopathy and findings that suggest a syndromic diagnosis.
In conclusion, the risk versus benefit of therapeutic hypothermia for neonates with congenital brain anomalies and syndromic disorders who present with signs of perinatal asphyxia is uncertain. Larger numbers of cases from multiple institutions or a randomized, controlled trial will be necessary to better understand and standardize an approach to these patients, especially considering the lack of other therapeutic interventions.
